Mira Pharmaceuticals Inc (MIRA)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Mira Pharmaceuticals Inc Stock (MIRA) Company Profile

Mira Pharmaceuticals Inc

Healthcare (1091)

813-369-5150

1200 BRICKELL AVENUE, MIAMI

최신 SEC 제출 서류

MIRA's Discussions on Twitter

Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
MIRA Mira Pharmaceuticals Inc	0.9499	38.66M	0	-31.37M	-4.23M	-1.438
LLY Lilly Eli Co	1,160.59	1.02T	72.25B	25.28B	10.37B	27.78
JNJ Johnson Johnson	249.25	598.96B	97.93B	21.04B	17.80B	8.6278
ABBV Abbvie Inc	255.24	447.67B	62.82B	3.60B	19.98B	2.0274
MRK Merck Co Inc	125.52	307.25B	65.51B	8.93B	14.12B	3.5532
NVS Novartis Ag Adr	154.28	285.37B	54.66B	13.58B	16.05B	7.0171

Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스

Mira Pharmaceuticals Inc (MIRA) 재무 분석

Mira Pharmaceuticals Inc (MIRA)

Mira Pharmaceuticals Inc Stock (MIRA) Company Profile

Compare MIRA vs LLY, JNJ, ABBV, MRK, NVS

Mira Pharmaceuticals Inc 주식(MIRA)의 최신 뉴스

Andriy Mushak Net Worth (2026) - GuruFocus

Why Is MIRA (NASDAQ:MIRA) Non-Opioid Program in Focus? - Kalkine Media

MIRA Pharmaceuticals Reports Successful Formulation Results Supporting Development of MIRA-55 as a Non-Opioid Oral Therapy for Chronic Inflammatory Pain - ACCESS Newswire

symbol__ Stock Quote Price and Forecast - CNN

MIRA Pharmaceuticals (NASDAQ:MIRA) Advances Pain Program - Kalkine Media

MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 - Investing.com

MIRA Pharmaceuticals announces positive preclinical results for MIRA-55 - TipRanks

Mira Pharmaceuticals Oral Form Shows 'Positive' Results in Pre-Clinical Studies - Moomoo

MIRA Pharmaceuticals reports oral formulation progress for MIRA-55 By Investing.com - Investing.com Canada

MIRA Pharmaceuticals (NASDAQ: MIRA) reports encouraging preclinical data for non-opioid pain candidate MIRA-55 - Stock Titan

Experimental MIRA-55 pill shows brain and liver reach in pain studies - Stock Titan

MIRA Q3 2025 Earnings: Positive EPS Surprise Fails to Lift SharesEarnings Revision Report - DonanımHaber

Mira reports results on optimized oral formulation of SKNY-1 - BioWorld News

Mira Pharmaceuticals Says SKNY-1 in Obesity, Addiction Shows 'Favorable' Bioavailability in Preclinical Studies - Moomoo

MIRA Reports Positive Preclinical Data for SKNY-1 Program - TipRanks

MIRA Pharmaceuticals Reports Successful Formulation Results for SKNY-1, Its Oral Drug Candidate for Obesity and Addiction - ACCESS Newswire

MIRA Pharmaceuticals (MIRA) reports promising SKNY-1 preclinical pharmacokinetic and behavioral data - Stock Titan

MIRA's obesity-and-addiction drug shows brain and liver exposure - Stock Titan

MIRA SEC FilingsMira Pharma 10-K, 10-Q, 8-K Forms - Stock Titan

MIRA Pharmaceuticals Company Profile & Introduction - Moomoo

MIRA Pharmaceuticals Secures Worldwide Exclusive Rights to MIRA-55 and SKNY-1 - ACCESS Newswire

MIRA Q3 2025 Earnings: EPS Beats Estimates by 26.47% as Pre-Revenue Biotech Focuses on Pipeline ProgressEPS Miss Report - dars.gov.et

What's going on with MIRA Pharma stock Tuesday? - MSN

MIRAMira Pharmaceuticals Inc Options - Finviz

MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Whalen Matthew Pratt - Moomoo

MIRA Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director MacPherson Edward Cloustonmoomoo - Moomoo

MIRA Pharmaceuticals, Inc.(NasdaqCM:MIRA) added to Russell Microcap Growth Benchmark Index - marketscreener.com

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Growth Benchmark - marketscreener.com

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell Microcap Index - marketscreener.com

MIRA Pharmaceuticals, Inc.(NasdaqCM: MIRA) added to Russell 3000E Index - marketscreener.com

Price to earnings forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Enterprise value to revenue forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

Price to sales forward of MIRA Pharmaceuticals, Inc. – NASDAQ:MIRA - TradingView

MIRA Pharmaceuticals Reports New Preclinical Data Demonstrating Mira-55's Differentiated Mechanism of Action and Anxiolytic Activity Relative to THC - Black Hills Pioneer

MIRA Pharmaceuticals, Inc. Actuals & Estimates (FWB:K6S) - TradingView

MIRA Pharmaceuticals, Inc. Actuals & Estimates (MUN:K6S) - TradingView

MIRA Pharmaceuticals, Inc. Actuals & Estimates (TRADEGATE:K6S) - TradingView

K6S Forecast — Price Target — Prediction for 2027 - TradingView

MIRA Forecast — Price Target — Prediction for 2027 - TradingView

MIRA Flat at Open - Baystreet.ca

MIRA Pharmaceuticals (NASDAQ:MIRA) Reports Positive Preclinical Data for Mira-55 in Chronic Inflammatory Pain - grafa.com

Mira Pharmaceuticals reports preclinical data on pain drug candidate - Investing.com

MIRA Pharmaceuticals Advances Mira-55 for Chronic Pain Relief - GuruFocus

Mira Pharmaceuticals reports preclinical data on pain drug candidate By Investing.com - Investing.com Australia

MIRA Unveils Differentiated Preclinical Data for Mira-55 - TipRanks

MIRA’s Mira-55 eases anxiety in preclinical tests, unlike THC - Stock Titan

MIRA reports preclinical Mira-55 data showing distinct mechanism, anxiolytic activity vs THC - TradingView

MIRA Pharmaceuticals (NASDAQ: MIRA) highlights differentiated Mira-55 preclinical profile vs. THC - Stock Titan

MIRA Pharmaceuticals Q3 2025 Earnings: EPS Beats Estimates Despite Revenue Absence, Stock Slightly Down - dars.gov.et

MIRA Pharmaceuticals (MIRA) Edges Lower, Holds Above Key Support at $0.9Gap and Reverse - dars.gov.et

MIRA Pharmaceuticals Submits Phase 2a Clinical Trial Protocol to FDA for Ketamir-2 in Chemotherapy-Induced Peripheral Neuropathy - ACCESS Newswire

Mira Pharmaceuticals Inc (MIRA) 재무 분석

매출

순이익

현금흐름

주당 순 이익

MIRA과 유사한 종목